Zai Lab CEO Sells Shares Worth Approximately $2.6 Million After Exercising Stock Options

On May 15 and 18, 2026, Du Ying, CEO of Zai Lab Ltd (NASDAQ: ZLAB), exercised stock options in two tranches to acquire a total of 100,000 American Depositary Shares (ADS) and immediately sold the same number of shares in the open market under a Rule 10b5-1 trading plan. The exercise price was $1.74 per share, and the weighted-average selling prices were $20.74 and $18.99, respectively, generating total proceeds of approximately $1.99 million (about KRW 2.6 billion). Because this was a simultaneous option exercise and public-market sale rather than a net purchase, CEO Du Ying’s direct stake remains at roughly 1.12 million shares.

The company recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its DLL3-targeting antibody-drug conjugate candidate, zocilurtatug pelitecan. In its first-quarter results, Zai Lab reported revenue of about $99.6 million and a net loss, maintaining its strategy of heavy R&D investment focused on its oncology pipeline. (zailaboratory.com)

Zai Lab is a commercial-stage global biopharmaceutical company based in China and the U.S. Since its founding in 2014, it has concentrated on the development and commercialization of innovative therapies in oncology, immunology, neuroscience and infectious diseases. Listed on both Nasdaq and the Hong Kong Stock Exchange, the company is pursuing the Chinese and global markets through products such as the ovarian cancer treatment Zejula and the brain-tumor therapy Optune, as well as through multiple licensing partnerships. (zailaboratory.com/about-us/)